Shattuck Labs reports positive Phase 1 data for Crohn’s disease candidate SL-325
Compartilhar
Shattuck Labs (NASDAQ:STTK) announced positive top-line results from its Phase 1 clinical trial of SL-325, a novel Death Receptor 3 (DR3) blocking antibody.
